Collecting and reporting data on patients receiving stem cell transplants

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to systematically collect, analyze, and report data on patients undergoing hematopoietic stem cell transplantation, either autologous or allogeneic, for various hematological malignancies. It focuses on patients receiving standard preparative regimens, ensuring that the data collected adheres to IRB-approved protocols. The goal is to enhance understanding of treatment efficacy in cases where specific research questions are not being addressed.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Planned standard of care dose intensive therapy and either an allogeneic or autologous bone marrow transplant

Exclusion Criteria:

Participation in any other treatment research protocol

Where it's running

• Wake Forest Baptist Health
  Winston-Salem, North Carolina, United States Recruiting

Study contacts

• Principal investigator: Dianna Howard, MD — Wake Forest University Health Sciences
• Study coordinator: Dianna Howard, MD
• Email: dhoward@wakehealth.edu

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Stem cell transplant using a specific preparative regimen for blood cancers

  This study is testing a new way to prepare for a stem cell transplant using a special combination of medications and radiation to see if it helps people with acute leukemia who are in remission.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT05805605

• Combining an unmodified family (haplo‑identical) donor graft with cord blood for transplant

  This trial will test whether giving an unmodified haplo‑identical donor graft followed by a cord blood graft with post‑transplant cyclophosphamide helps people with high‑risk AML, ALL, or MDS stay free of disease.

  Recruiting Phase 2 Case Comprehensive Cancer Center · Cleveland, Ohio · NCT06904482

• Study of crushed venetoclax tablets dissolved in liquid for pediatric patients

  This study tests if crushing venetoclax tablets and mixing them with liquid helps children with blood cancers absorb the medication better and stay safe while taking it.

  Recruiting at 5 sites Children's Hospital Medical Center, Cincinnati · Aurora, Colorado and 5 other locations · NCT06131801

• Comparing T Cell Depletion Methods for Blood Cancer Treatment

  This study is testing different ways to prevent complications after a stem cell transplant for blood cancer to see which method helps patients stay healthy and cancer-free longer.

  Recruiting at 17 sites Phase 2 University of Birmingham · Cardiff, Wales and 16 other locations · NCT04888741

• Oral treatment with LP-118 for patients with various blood cancers

  This study is testing a new oral treatment called LP-118 to see if it is safe and can help people with certain types of blood cancers that have come back or didn’t respond to other treatments.

  Recruiting at 8 sites Phase 1 Newave Pharmaceutical Inc · Chicago, Illinois and 7 other locations · NCT04771572

• Hematopoietic stem cell transplant for blood cancers

  This study is testing two different ways of doing stem cell transplants for people with blood cancers to see which method works better and is safer.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT03314974

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.